"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 3 | 4 |
| 1996 | 1 | 0 | 1 |
| 1997 | 4 | 0 | 4 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 2 | 2 | 4 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 1 | 4 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 7 | 1 | 8 |
| 2017 | 2 | 4 | 6 |
| 2018 | 0 | 1 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A?Randomized Trial. Ann Thorac Surg. 2023 04; 115(4):929-938.
-
Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
-
Randomized Trial of Aspirin Versus Warfarin After Transcatheter Aortic Valve Replacement in Low-Risk Patients. Circ Cardiovasc Interv. 2021 01; 14(1):e009983.
-
Evaluation of dosing and safety outcomes of low-dose prophylactic warfarin in children after cardiothoracic surgery. Am J Health Syst Pharm. 2020 06 23; 77(13):1018-1025.
-
Venous Thromboembolism Prophylaxis: Safe, but Still Provocative? Thromb Haemost. 2019 11; 119(11):1716-1718.
-
Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. Pharmacotherapy. 2019 10; 39(10):1030-1035.
-
Embolic stroke of undetermined source in a young woman. Am J Hematol. 2019 09; 94(9):1044-1048.
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
-
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. Am J Epidemiol. 2018 11 01; 187(11):2439-2448.